Business Context and Reporting Period
Company: Arrowhead Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: August 4, 2026
Reporting Period: Fiscal year ended June 30, 2026
This filing announces the company's fiscal 2026 financial results. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1) but are not present in the Form 8-K cover page text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the announcement of the fiscal 2026 results.
Guidance, Outlook, and Risks
Management Commentary: The company announced and commented on its fiscal 2026 results on August 4, 2026.
Legal Disclaimer: In accordance with General Instruction B.2 of Form 8-K, the information in this report and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section. It shall not be deemed incorporated by reference in any other filing unless expressly set forth by specific reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net income, and cash flow figures.
- Verify the company's cash position and runway given the biotech sector context.
- Check for any updated clinical trial milestones or regulatory guidance mentioned in the press release.
- Confirm if the "commentary" in the press release includes revised fiscal 2027 guidance.